{"resourceType": "EvidenceVariable", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "236965", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-313960", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "313960"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85798"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73215"}], "name": "End_stage_kidney_disease313960", "title": "OutcomeDefinition: End-stage kidney disease", "shortTitle": "End-stage kidney disease", "status": "active", "description": "End-stage kidney disease", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "relatedArtifact": [{"type": "part-of", "resourceReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "handling": "dichotomous", "meta": {"versionId": "49", "lastUpdated": "2024-08-23T17:26:46.939Z"}, "url": "https://fevir.net/resources/EvidenceVariable/236965", "id": "236965", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-definition", "valueCodeableReference": {"concept": {"text": "End-stage kidney disease"}}}]}